Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

Peer Review reports

Original Submission
23 Oct 2020	Submitted	Original manuscript
11 Mar 2021	Author responded	Author comments - Quisette P Janssen
Resubmission - Version 2
11 Mar 2021	Submitted	Manuscript version 2
Publishing
14 Mar 2021	Editorially accepted
23 Mar 2021	Article published	10.1186/s12885-021-08031-z

Back to article page